Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease | Zendy

Lisa A. Jackson | Zendy; Douglas K. Stewart | Zendy; S.-P. Wang | Zendy; Dennis B. Cooke | Zendy; Truman Cantrell | Zendy; J. Thomas Grayston | Zendy

Open Access

Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease

Author(s) -

Lisa A. Jackson,

Douglas K. Stewart,

S.-P. Wang,

Dennis B. Cooke,

Truman Cantrell,

J. Thomas Grayston

Publication year - 1999

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/44.3.411

Subject(s) - azithromycin , medicine , chlamydia , placebo , serology , coronary artery disease , randomized controlled trial , antibody , surgery , immunology , antibiotics , pathology , microbiology and biotechnology , alternative medicine , biology

A pilot study of azithromycin treatment following percutaneous coronary revascularization procedures was performed to assess safety and the effect of azithromycin treatment on anti-Chlamydia pneumoniae antibody titres. Patients were randomized to a 1 month course of azithromycin (total dose of 8.0 g) or placebo. Safety and compliance were assessed at 2 and 4 weeks and serological testing was performed on samples obtained at enrolment and at 6 months post-enrolment. Azithromycin was well tolerated at this dose. No effect of treatment on antibody titres was demonstrated. These results support further clinical trials to assess the effect of azithromycin treatment on cardiovascular disease outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research